Pandemic Influenza Preparedness and Response 2016-2021

The Pandemic Influenza Preparedness and Response 2016-2021 is a Master Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). The contract is designed to support medical countermeasure (MCM) development, manufacturing, storage, and testing specifically focused on pandemic influenza preparedness and response. The vehicle enables HHS to rapidly acquire specialized vaccine-related services, including antigen development, clinical studies, bulk lot manufacturing, storage and stability testing, and vaccine stockpile management.

Key task orders under this IDIQ consistently involve three primary contractors: Sanofi Pasteur Inc., Protein Sciences Corporation, and GlaxoSmithKline, LLC. Task orders typically range from approximately $50,000 to $40 million, with performance periods spanning several months to multiple years. Common scopes include storage and stability testing of vaccine bulk lots and final containers, manufacturing of clinical and commercial vaccine lots, conducting non-clinical and clinical studies for vaccine candidates, and developing adjuvants for influenza vaccines. All task orders were firm fixed price with no set-aside designations, and performance locations primarily included contractors' facilities in Pennsylvania (Sanofi Pasteur in Swiftwater), North Carolina (GlaxoSmithKline in Research Triangle Park), and Connecticut (Protein Sciences in Meriden). The contract supported broader pandemic preparedness efforts, including early COVID-19 vaccine research and development initiatives.